ATRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-05), Antares Pharma's share price is $5.59. Antares Pharma's Owner Earnings per Share (TTM) ended in Mar. 2022 was $0.31. It's Price-to-Owner-Earnings for today is 18.03.
The historical rank and industry rank for Antares Pharma's Price-to-Owner-Earnings or its related term are showing as below:
During the past 13 years, the highest Price-to-Owner-Earnings of Antares Pharma was 421.25. The lowest was 9.00. And the median was 70.00.
As of today (2024-05-05), Antares Pharma's share price is $5.59. Antares Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $0.24. Therefore, Antares Pharma's PE Ratio for today is 23.29.
As of today (2024-05-05), Antares Pharma's share price is $5.59. Antares Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was $0.24. Therefore, Antares Pharma's PE Ratio without NRI for today is 23.29.
During the past 13 years, Antares Pharma's highest PE Ratio without NRI was 489.00. The lowest was 8.68. And the median was 15.43.
The historical data trend for Antares Pharma's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | - | - | - | 83.13 | 10.20 |
Antares Pharma Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | 141.72 | 73.90 | 27.37 | 10.20 | 13.14 |
For the Medical Instruments & Supplies subindustry, Antares Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Antares Pharma's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Antares Pharma's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 5.59 | / | 0.31 | |
= | 18.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma (NAS:ATRS) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Antares Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Carmen B Volkart | director | C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127 |
Peter C Richardson | officer: See Remarks | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Fred M Powell | officer: Executive Vice President & CFO | C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Thomas J Garrity | director | |
Roche Robert P Jr | director | 41 MOORES ROAD FRAZER PA 19355 |
Leonard S Jacob | director | C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022 |
Peter J Graham | officer: See Remarks | 315 E. 72ND ST., APT 5E, NEW YORK NY 10021 |
Peter Greenleaf | director | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Anton Gueth | director | |
Robert F Apple | director, officer: President & CEO | C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422 |
Marvin Samson | director | |
Jacques Gonella | director | C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341 |
James Patrick Tursi | officer: EVP, Chief Medical Officer | 106 ASHLEY COURT, MOORESTOWN NJ 08057 |
Keith E Muckenhirn | officer: VP/Controller & Interim CFO | C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447 |
From GuruFocus
By PRNewswire PRNewswire • 05-12-2022
By GuruFocusNews GuruFocusNews • 04-13-2022
By PRNewswire PRNewswire • 05-16-2022
By GuruFocus Research GuruFocus Editor • 05-18-2022
By PRNewswire PRNewswire • 05-03-2022
By PRNewswire PRNewswire • 04-28-2022
By PRNewswire PRNewswire • 06-08-2022
By PRNewswire PRNewswire • 05-06-2022
By GuruFocus Research GuruFocus Editor • 08-16-2022
By GuruFocus Research GuruFocus Editor • 08-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.